Alteogen has shown growth in its performance for the first quarter of this year (January to March), leading to an increase in its stock price during the after-market period (after 3:40 p.m. to 8 p.m.) on the 13th.
Alteogen shares traded at 360,000 won in the after-market at 6 p.m. on that day. This is 7.14% (24,000 won) higher than the previous day's closing price. It also rose 3.44% (12,000 won) compared to the regular market closing price on that day.
Alteogen reported revenues of 83.6 billion won and operating profits of 61 billion won after the regular market closed on that day. Compared to the same period last year, revenues have increased by 2.4 times and operating profits by 3.5 times.
Although Alteogen's stock price has undergone adjustments due to the patent infringement lawsuit against Merck regarding Haloadime, assessments suggest that the company's value is likely to increase in the future.
Kim Seon-a, a researcher at Hana Securities, noted, "The SC formulation has become a necessity rather than an option, and the number of partners looking to apply Alteogen's ALT-B4 in clinical stages is expected to increase." He added, "In the patent dispute, we are also predicting a high likelihood of Merck's victory," and said, "If the cash inflow accelerates, the value of Alteogen will rise further."